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the three arms: gastrointestinal g3-4 in 7 (1%) cycles, asthenia g3 in 
18 (4%) cycles, neurological g3 in 8 (2%) cycles and skin toxicity g3 
in 3 (<1%) cycles. Response rate as assessed after three cycles and at 
the end of treatment was: arm A=22%/24%, arm B=23%/12%, arm 
C=33%/28%. As March 2007, 129 patients died (44 arm A, 50 arm B 
and 35 arm C). The median survival is 10.7 mo, 8.9 mo and 14.6 mo in 
the arm A, B and C, respectively; HR: B vs A 1.17 (95% CI 0.77-1.78), 
C vs A 0.65 (95% CI0.77-1.78).The 1-yr progression free survival rate 
is:arm A 18%, arm B 8% and arm C 23%. 
Conclusion: All the arms are characterized by a mild toxicity, with 
a worse proﬁle for arm B. Even in the absence of a statistical signiﬁ-
cance, there is a trend of better efﬁcacy of the arm C versus A and 
B, which conﬁrm the role of platinum-based therapy in treatment of 
NSCLC.
P2-292 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
A randomized Phase 3 trial of gemcitabine with or without 
carboplatin in performance status 2 (PS2) patients with advanced 
(stage IIIB with pleural effusion or IV) non-small-cell lung cancer 
(NSCLC)
Reynolds, Craig1 Conkling, Paul2 Richards, Donald A.3 Fitzgibbons, 
James F.4 Arseneau, James C.5 Boehm, Kristi A.6 Asmar, Lina6 
Bromund, Jane7 Peng, Guangbin7 Obasaju, Coleman K.7 
1 US Oncology, Ocala, FL, USA 2 US Oncology, Norfolk, VA, USA 3 
US Oncology, Tyler, TX, USA 4 US Oncology, Eugene, OR, USA 5 US 
Oncology, Albany, NY, USA 6 US Oncology, Dallas, TX, USA 7 Eli Lilly 
and Company, Indianapolis, IN, USA 
Background: The optimal treatment of patients with advanced NSCLC 
and PS2 has not been resolved. A retrospective analysis of 99 patients 
with PS2 in CALGB 9730 (Lilenbaum, JCO 2005) demonstrated im-
proved survival associated with combination carboplatin-paclitaxel ver-
sus paclitaxel alone (median overall survival=4.7 vs. 2.4 mos., p=.019). 
Gemcitabine-carboplatin (GC) is an active doublet in advanced NSCLC 
and is at least as active as paclitaxel-carboplatin (PC) in PS2 patients 
(ECOG 1599, Tester ASCO 2004). A prospective validation of the 
activity of GC is needed, which is addressed by comparing GC versus 
gemcitabine (G) alone in this setting.
Methods: 161 chemonaïve patients with advanced NSCLC and PS2 
were randomly assigned to G 1250 mg/m2 alone on Days 1 and 8 or GC 
(G 1000 mg/m2 Days 1 and 8 followed by C AUC=5 on Day 1). Cycles 
were repeated every 21 days for 6 cycles or until disease progression or 
intolerable toxicity. The primary endpoint was median survival.
Characteristics/Results G alone GC combination
N enrolled 81 80
Median age (range) 75 (45-89) 73 (46-88)
Male:Female 57:43 54:46
N receiving drug 72 69
Mean cycles (range) 3.3 (1-6) 4.0 (1-6)
Relative dose intensity, % G:C 91:NA 72:90
G3 and 4 neutropenia, % pts G3:4 2.8:1.4 15.9:11.6
G3 and 4 thrombocytopenia, % pts G3:4 0:0 8.7:10.1
G3 and 4 febrile neutropenia, % pts G3:4 0:0 0:0
G3 and 4 anemia, % pts G3:4 1.4:0 7.2:0
N assessed for response 70 67
CR, % O O
PR, % 7.1 31.3
SD, % 35.7 31.3
PD, % 17.1 14.9
Unknown response, % 40.0 22.4
FACT-L trial outcome index (mean) 
Baseline 49.4 50.6
Cycle 1 49.27 50.15
Cycle 2 51.92 54.09
Cycle 3 51.08 55.27
Cycle 4 51.09 57.43
Cycle 5 50.11 59.53
Median survival following randomization (mos) 5.22 6.97
95% CI 3.61, 7.92 4.53, 10.81
Events:censored 45:24 44:23
Log-rank P value 0.489  
Median PFS following randomization (mos) 2.79 4.01
95% CI 1.84, 4.14 2.63, 6.14
Events:censored 52:17 48:19
Log-rank P value 0.424  
Cox regression model of survival Hazard ratio P value
GC vs G 0.84 0.415
Baseline LDH 1.70 0.017
Baseline weight 1.50 0.057
Conclusions: GC resulted in an improved response rate, overall 
survival, and progression-free survival time, but differences were not 
statistically signiﬁcant. As expected, G3-4 toxicities were greater with 
GC. Patients receiving GC had improved FACT-L quality-of-life scores 
at each cycle of treatment. Elevated baseline LDH and weight were 
associated with worsened outcome.
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Background: Pemetrexed (P), a multi-targeted antifolate, was syner-
gisitic with gemcitabine (G) in preclinical models. A Phase 1/2 trial was 
conducted to determine the optimal dose and sequence of the drugs and 
their effect on pts with advanced NSCLC.
Methods: In Phase 1, pts with advanced solid tumors were enrolled. 
In Phase 2, pts had Stage IIIB (with pleural effusion) or IV NSCLC, 
